Liquidia Inc. (LQDA) - Long-Term Debt to Capital Coefficient

Liquidia Inc. - graphic logo of issuer LQDA

The market trend for Liquidia Corporation (LQDA) shown on this price chart reflects the dynamics of a company implementing ESG principles through plant modernization and the reduction of plastics in inhalers, with the indicator standing at 0.65. The business relies on partnerships with laboratories to develop pulmonary disease medications, yet faces patent disputes and regulatory barriers that hinder product commercialization.

Liquidia Corp (LQDA): Long-Term Debt to Equity from 07/04/2022 to 10/31/2026
Signature product of Liquidia Corporation

The long-term debt-to-equity ratio determines the proportion of liabilities with a maturity exceeding one year relative to shareholders' equity, allowing for an assessment of financial leverage and long-term borrowing risks. By analyzing the history of the long-term debt-to-equity ratio, investors confirm the stability of Liquidia Corporation (LQDA), where a steady cash flow from pulmonary hypertension drugs ensures a confident increase in the business's financial health.

Analysis of competing companies

Haleon PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital KVUE|VRNA (Verona Pharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital MENS (Jyong Biotech Ltd)|Long-Term Debt to Capital ligand.com LGND|AMRX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient PRGO (Perrigo Company PLC)|Alvotech Corp (ALVO) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Galapagos Corp|ANIP (ANI Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital mannkindcorp.com|Long-Term Debt to Equity Ratio AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Pharmaceuticals) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity ARS Pharma SPRY|Theravance Corp (TBPH) - Long-Term Liabilities to Capital|AQST: Long-Term Debt to Equity Ratio|scPharmaceuticals Inc. - Long-Term Loans to Capital Ratio|TECX: Long-Term Debt to Capital|Tonix Pharma - Long-Term Debt to Capital Coefficient|SXTC (SXT Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Eupraxia Pharma EPRX|Long-Term Debt to Equity BioHarvest Sciences (BHST)|EXOZ (invizyne.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Oramed Pharmaceuticals Inc. ORMP|Entera Bio Ltd - Long-Term Debt to Equity|MindWalk - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital ABVC BioPharma, Inc ABVC|Cumberland Pharmaceuticals (CPIX) - Long-Term Debt to Equity|Long-Term Indebtedness to Equity quantumbiopharma.com QNTM|Long-Term Debt to Equity Ratio FGEN|Long-Term Debt to Capital Telomir Pharmaceuticals Inc|Long-Term Debt to Capital RANI|Ratio of Long-Term Indebtedness to Capital synergychc.com|Long-Term Debt to Capital RLYB (Rallybio)|LEXX: Long-Term Debt to Capital Ratio|Pulmatrix - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Pheton Holdings Ltd PTHL|APM: Long-Term Debt to Capital|Lyra Therapeutics Inc (LYRA) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio IBO|TNFA: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital YCBD|Long-Term Debt to Equity Ratio PainReform Ltd PRFX|Long-Term Debt to Equity Altamira Therapeutics Ltd. CYTO|Lipella Pharma (LIPO) - Long-Term Liabilities to Capital|OPTN - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient PIRS (pieris.com)|Procaps (PROC) - Long-Term Debt to Equity|Long-Term Liabilities to Equity PTPI (Petros Pharmaceuticals Inc)|Long-Term Debt to Equity Qilian International Holding Group Limited|Long-Term Liabilities to Capital ACELYRIN Inc. SLRN|Long-Term Debt to Equity TFF Pharmaceuticals (TFFP)